Cargando…

Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer

Starting in 2014, large phase III clinical trials began to disclose the study results of using programmed death (PD)-1 immune checkpoint inhibitors (ICIs) (pembrolizumab, nivolumab) and PD-ligand (L)1 (atezolizumab, durvalumab, avelumab) ICIs immunotherapy in patients with advanced head and neck squ...

Descripción completa

Detalles Bibliográficos
Autor principal:	Kok, Victor C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7058818/ https://www.ncbi.nlm.nih.gov/pubmed/32185135 http://dx.doi.org/10.3389/fonc.2020.00268

Ejemplares similares

Further investigation of blockade effects and binding affinities of selected natural compounds to immune checkpoint PD-1/PD-L1
por: Li, Huifang, et al.
Publicado: (2022)

Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade
por: Nardone, Valerio, et al.
Publicado: (2021)

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
por: Ma, Weijie, et al.
Publicado: (2016)

Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies
por: Ilcus, Cristina, et al.
Publicado: (2017)

Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma
por: Manukian, Gregor, et al.
Publicado: (2019)

PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach
por: Fameli, Antonella, et al.
Publicado: (2022)

A Novel Computational Framework for Predicting the Survival of Cancer Patients With PD-1/PD-L1 Checkpoint Blockade Therapy
por: Su, Xiaofan, et al.
Publicado: (2022)

Immunotherapy of alveolar echinococcosis via PD‐1/PD‐L1 immune checkpoint blockade in mice
por: Wang, Junhua, et al.
Publicado: (2018)

A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints
por: Li, Yongshu, et al.
Publicado: (2016)

Relapsing Polychondritis following PD-1 Blockade by an Immune Checkpoint Inhibitor
por: Mutoh, Tomoyuki, et al.
Publicado: (2023)

Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers
por: Yang, Bo, et al.
Publicado: (2018)

Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC
por: Lin, Weimin, et al.
Publicado: (2018)

Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion
por: Dong, Peixin, et al.
Publicado: (2018)

Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma
por: Placke, Jan-Malte, et al.
Publicado: (2021)

Ethanol Exposure Up-Regulates PD-L1/PD-1 Immune Checkpoint Pathway and Promotes Mammary Tumor Development
por: Xu, Wenhua, et al.
Publicado: (2022)

A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
por: Koopmans, Iris, et al.
Publicado: (2018)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer
Publicado: (2021)

Targeted Glucose or Glutamine Metabolic Therapy Combined With PD-1/PD-L1 Checkpoint Blockade Immunotherapy for the Treatment of Tumors - Mechanisms and Strategies
por: Ma, Guofeng, et al.
Publicado: (2021)

Prospective Evaluation of All-lesion Versus Single-lesion Radiotherapy in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors
por: Schubert, Philipp, et al.
Publicado: (2020)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer(1)
Publicado: (2020)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer(1)
por: Tu, Megan M., et al.
Publicado: (2019)

Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade
por: Tian, Tian, et al.
Publicado: (2021)

Characterization of the Immune Response to PD-1 Blockade during Chemoradiotherapy for Head and Neck Squamous Cell Carcinoma
por: Callejas-Valera, Juan L., et al.
Publicado: (2022)

In vivo and in situ programming of tumor immunity by combining oncolytics and PD-1 immune checkpoint blockade
por: Bartee, Eric, et al.
Publicado: (2017)

IL-21 Is an Accomplice of PD-L1 in the Induction of PD-1-Dependent Treg Generation in Head and Neck Cancer
por: Zhao, Yi, et al.
Publicado: (2021)

Immune-related adverse events of anti-PD-1 immune checkpoint inhibitors: a single center experience
por: Sebestyén, Enikő, et al.
Publicado: (2023)

Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer
por: Mussafi, Ofek, et al.
Publicado: (2022)

Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation
por: Roberts, Alexander, et al.
Publicado: (2021)

Glutaminolysis Mediated by MALT1 Protease Activity Facilitates PD-L1 Expression on ABC-DLBCL Cells and Contributes to Their Immune Evasion
por: Xia, Xichun, et al.
Publicado: (2018)

A Retrospective Analysis of a Cohort of Patients Treated With Immune Checkpoint Blockade in Recurrent/Metastatic Head and Neck Cancer
por: Bila, Michel, et al.
Publicado: (2022)

Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes
por: Zheng, Dan, et al.
Publicado: (2022)

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
por: Koyama, Shohei, et al.
Publicado: (2016)

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
por: Hung, Alice L., et al.
Publicado: (2018)

Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade
por: Zhang, Fei, et al.
Publicado: (2017)

PD-1 Immune Checkpoint Blockade and PSGL-1 Inhibition Synergize to Reinvigorate Exhausted T Cells
por: Viramontes, Karla M., et al.
Publicado: (2022)

Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma
por: Song, Moo-Kon, et al.
Publicado: (2019)

Tackling Immune Targets for Breast Cancer: Beyond PD-1/PD-L1 Axis
por: Tabana, Yasser, et al.
Publicado: (2021)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

Plac1 Remodels the Tumor Immune Evasion Microenvironment and Predicts Therapeutic Response in Head and Neck Squamous Cell Carcinoma
por: Meng, Xiaoyan, et al.
Publicado: (2022)

Gut Microbiota: A Promising Milestone in Enhancing the Efficacy of PD1/PD-L1 Blockade Therapy
por: Zhou, Yuqing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2n14s4859b7m9soivn5qh0bd6a